Alkermes plc. Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax
Alkermes plc. (ALKS) reported Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax of $15.30 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax · last filed 2017-02-17
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, net of tax for fiscal 2014 was $15.30M.
- Alkermes plc. other comprehensive income (loss), reclassification adjustment from aoci on derivatives, net of tax for fiscal 2013 was -$594.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax 12 month |
|---|---|
| 2014-12-31 | $15.30M 10-K · filed 2017-02-17 |
| 2013-03-31 | -$594.00K 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |